menu
    • menu
    [{"orgOrder":0,"company":"Norgine","sponsor":"Faes Farma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Small molecule","year":"2020","type":"Agreement","leadProduct":"Potassium Chloride","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Norgine \/ Faes Farma S.A.","highestDevelopmentStatusID":"12","companyTruncated":"Norgine \/ Faes Farma S.A."},{"orgOrder":0,"company":"Norgine","sponsor":"Goldman Sachs Asset Management","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"NETHERLANDS","productType":"Small molecule","year":"2022","type":"Financing","leadProduct":"Sodium Chloride","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Norgine","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Powder For Solution","sponsorNew":"Norgine \/ Goldman Sachs Asset Management","highestDevelopmentStatusID":"12","companyTruncated":"Norgine \/ Goldman Sachs Asset Management"},{"orgOrder":0,"company":"Entrinsic bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sodium Chloride","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Entrinsic bioscience","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Entrinsic bioscience \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Entrinsic bioscience \/ Not Applicable"},{"orgOrder":0,"company":"Bio-Thera Solutions","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"CHINA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Sodium Chloride","moa":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Bio-Thera Solutions","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Bio-Thera Solutions \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Bio-Thera Solutions \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Sodium Chloride

    Menu

    Sodium Chloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bio-Thera Solutions

                            China arrow
                            Antibody Engineering
                            Not Confirmed

                            Bio-Thera Solutions

                            China arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Chloride

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Bio-Thera Solutions Announces Phase IB / IIA Trial for Bat6026 in Atopic Dermatitis

                            Details : BAT6026 is a novel OX40 agonist antibody being evaluated in phase 1/2 trials combined with sodium chloride injection for moderate to severe atopic dermatitis treatment.

                            Brand Name : BAT6026

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 01, 2024

                            Lead Product(s) : Sodium Chloride

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Entrinsic bioscience

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Entrinsic bioscience

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Chloride,Potassium Chloride,Magnesium Chloride

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            New Enterade Clinical Study Demonstrates Fewer Stopped Treatments and Lower GI Side Effects for Cancer Patient...

                            Details : Enterade® (sodium chloride) advanced oncology formula (a plant-based amino acid beverage) helps in reducing adverse gastrointestinal side effects for patients undergoing cancer treatment.

                            Brand Name : Enterade

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 27, 2023

                            Lead Product(s) : Sodium Chloride,Potassium Chloride,Magnesium Chloride

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Norgine

                            Netherlands arrow
                            Antibody Engineering
                            Not Confirmed

                            Norgine

                            Netherlands arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Chloride,Sodium Bicarbonate,Potassium Chloride

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Goldman Sachs Asset Management

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Norgine Announces Closing of Investment from Goldman Sachs Asset Management

                            Details : The macrogol in Movicol (sodium chloride) binds with water and retains it in the bowel. This allows the water to rehydrate and bulk the stool to trigger renewed colonic activity.

                            Brand Name : Movicol

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 15, 2022

                            Lead Product(s) : Sodium Chloride,Sodium Bicarbonate,Potassium Chloride

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Goldman Sachs Asset Management

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Norgine

                            Netherlands arrow
                            Antibody Engineering
                            Not Confirmed

                            Norgine

                            Netherlands arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Potassium Chloride,Sodium Chloride,Ascorbic Acid

                            Therapeutic Area : Gastroenterology

                            Study Phase : Approved

                            Sponsor : Faes Farma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Norgine B.V. Inks Exclusive Licence and Distribution deal for PLENVU

                            Details : Norgine signed exclusive licence and distribution agreements with Faes Farma S.A., Pharmacare Limited T/A Aspen Pharmacare and Swixx Biopharma to provide worldwide exposure to PLENVU.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 12, 2020

                            Lead Product(s) : Potassium Chloride,Sodium Chloride,Ascorbic Acid

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Approved

                            Sponsor : Faes Farma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth